Expanded Bioanalytical Services for Biotherapeutics From the Aptuit, Inc. Center for Drug Discovery & Development in Verona, Italy

Published: Nov 29, 2012

Greenwich, CT, November 29, 2012 – Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that Aptuit provides integrated bioanalytical services for biotherapeutics, such as large molecules, proteins and enzymes from The Aptuit Center for Drug Discovery & Development in Verona, Italy.

When making the announcement, Mr. Needleman cited Aptuit’s substantial range of pharmacology expertise and capabilities to support the development of biologicals for the translational disease relevant models, including oncology, inflammatory diseases, metabolic disorders such as diabetes, psychiatry and neurology, neurodegeneration, pain and infections. He said that the company’s expertise in immunological biology in human and preclinical species has enhanced Aptuit’s reputation for quality work related to high risk compounds.

John Chappell, Manager, Applied Immunology and Biopharmaceutical Development, stressed that Aptuit’s integrated discovery and preclinical services provided from the Verona location employ sophisticated equipment and detection technologies. “The breadth of our capabilities bring added value to clients who have been dealing with several suppliers to get the data they need. When clients choose to partner with Aptuit from our single, integrated site, they experience convenience, time and cost savings, and importantly, an exceptional level of quality performance that is the result of our well established collaborative expertise,” he said.

It was also noted that Aptuit’s capabilities in bioanalytical therapeutics can serve as part of Aptuit INDiGO®, an accelerated route to First In Man, as short as six to 12 months, much less than the industry standard and fully compliant with U.S. and European regulatory guidelines.

Mr. Needleman added, “Aptuit’s Glasgow facility also has a legacy of expert bioanalytical services in sterile fill finish for Phase I studies that may be integrated with the competencies of our other global facilities. All of our facilities maintain the highest quality protocols that are consistent from site to site. Within the Aptuit organization, expert consultancy in biotherapeutics strategy and regulatory support are available. Consultants with real world experience are accessible throughout the development cycle, including assistance during the complex regulatory process. EU and U.S. regulatory submissions can be written by our technical experts and submitted electronically, or in paper or hybrid forms as needed.”

For more information, please contact John Chappell at john.chappell@aptuit.com. For press inquiries or to request an interview, please contact Maria Garvey, Delfino Marketing at 914-747-1400 or maria@delfino.com.

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting and Aptuit INDiGOÒ (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

For more information about Aptuit, visit www.aptuit.com

Back to news